BioMarin Pharmaceutical (BMRN) News Today $62.56 +0.59 (+0.95%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right NowNovember 20 at 10:22 AM | msn.comEULAV Asset Management Buys 15,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)EULAV Asset Management lifted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 12.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 131,000 shares of the biotechnolNovember 20 at 8:54 AM | marketbeat.comHowe & Rusling Inc. Grows Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Howe & Rusling Inc. grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 101.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 49,652 shares of the biotechnology company's sNovember 20 at 8:02 AM | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Earns Outperform Rating from Analysts at Wolfe ResearchNovember 19 at 1:33 AM | americanbankingnews.comCautious Optimism: Hold Rating on BioMarin Amid Promising Trial Data and Sector RisksNovember 18 at 6:30 PM | markets.businessinsider.comBioMarin : Real-World Evidence Supports Safety, Efficacy Of VOXZOGO In Children With AchondroplasiaNovember 18 at 5:44 AM | markets.businessinsider.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Sumitomo Mitsui Trust Group Inc.Sumitomo Mitsui Trust Group Inc. grew its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 4.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 456,097 shares of the biotechnoloNovember 17, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 1-Year Low Following Insider SellingNovember 17, 2024 | americanbankingnews.comWolfe Research Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Outperform RecommendationNovember 16, 2024 | msn.comBioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024November 16, 2024 | prnewswire.comComgest Global Investors S.A.S. Has $713,000 Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Comgest Global Investors S.A.S. decreased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 93.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 10,147 shares of the biotechnology company's stock after selliNovember 16, 2024 | marketbeat.comLos Angeles Capital Management LLC Acquires New Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Los Angeles Capital Management LLC bought a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,098 shares of the biotechnology company's stock,November 16, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells $350,300.86 in StockNovember 15, 2024 | insidertrades.comBioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 1-Year Low on Insider SellingBioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 1-Year Low Following Insider SellingNovember 15, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Analysts at Wolfe ResearchWolfe Research started coverage on shares of BioMarin Pharmaceutical in a research note on Friday. They issued an "outperform" rating and a $95.00 price objective on the stock.November 15, 2024 | marketbeat.comBioMarin initiated with an Outperform at Wolfe ResearchNovember 14, 2024 | markets.businessinsider.comWCM Investment Management LLC Buys 10,485 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)WCM Investment Management LLC increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 162.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,945 shares of the biotechnology company's stock afterNovember 13, 2024 | marketbeat.comImplied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock OptionsNovember 12, 2024 | msn.comPrincipal Financial Group Inc. Has $32.20 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Principal Financial Group Inc. decreased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 29.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 458,039 shares of the biotechnology companyNovember 12, 2024 | marketbeat.comHere’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)November 8, 2024 | msn.comNational Pension Service Acquires 13,878 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)National Pension Service raised its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 4.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 345,387 shares of the biotechnology company's stocNovember 8, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Has $14.81 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Robeco Institutional Asset Management B.V. raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 157.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 210,666 shares of the biotechnology cNovember 7, 2024 | marketbeat.comBioMarin to Participate in Three Upcoming Investor ConferencesNovember 6, 2024 | prnewswire.comBioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at WedbushWedbush upgraded BioMarin Pharmaceutical to a "strong-buy" rating in a research note on Monday.November 6, 2024 | marketbeat.comAlphaCentric Advisors LLC Increases Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)AlphaCentric Advisors LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 97.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,500 shares of the biotechnology company's stock afterNovember 5, 2024 | marketbeat.comLeerink Partnrs Brokers Decrease Earnings Estimates for BMRNBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Research analysts at Leerink Partnrs cut their FY2024 EPS estimates for shares of BioMarin Pharmaceutical in a note issued to investors on Wednesday, October 30th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology cNovember 4, 2024 | marketbeat.comF M Investments LLC Acquires New Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)F M Investments LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 22,073 shares of the biotechnology company's stock, valued at approximately $1November 3, 2024 | marketbeat.comRice Hall James & Associates LLC Has $726,000 Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Rice Hall James & Associates LLC reduced its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 50.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,327 shares of the biotechnolNovember 2, 2024 | marketbeat.comBioMarin Reports 28% Jump in RevenueNovember 1, 2024 | fool.comBioMarin's Pipeline Faces Skepticism As Analyst Questions Future GrowthNovember 1, 2024 | benzinga.comWilliam Blair Downgrades BioMarin Pharmaceutical (BMRN)November 1, 2024 | msn.comFY2024 EPS Estimates for BMRN Increased by Cantor FitzgeraldBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities research analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for BioMarin Pharmaceutical in a research report issued to clients and investors on Wednesday, October 30th. Cantor Fitzgerald analyst O. Brayer now forecaOctober 31, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by abrdn plcabrdn plc increased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 6.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 527,681 shares of the biotechnOctober 31, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by AnalystsBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-three research firms that are currently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and fOctober 31, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $81.00 by Analysts at CitigroupCitigroup decreased their price target on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a "neutral" rating for the company in a research note on Wednesday.October 30, 2024 | marketbeat.comBiomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...October 30, 2024 | finance.yahoo.comScotiabank Remains a Hold on BioMarin Pharmaceutical (BMRN)October 30, 2024 | markets.businessinsider.comBioMarin Pharmaceutical (BMRN) Receives a Buy from Cantor FitzgeraldOctober 30, 2024 | markets.businessinsider.comRoyal Bank of Canada Reiterates "Sector Perform" Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $80.00 price target on shares of BioMarin Pharmaceutical in a research note on Wednesday.October 30, 2024 | marketbeat.comUBS Group Increases BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $106.00UBS Group increased their target price on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a "buy" rating in a research note on Wednesday.October 30, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings ResultsBioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. The business had revenue of $746.00 million for the quarter, compared to analyst estimates of $703.37 million. During the same period last year, the firm earned $0.26 earnings per share. The company's quarterly revenue was up 28.4% on a year-over-year basis.October 30, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 52-Week Low After Earnings MissBioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month Low on Disappointing EarningsOctober 30, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Lowered to "Market Perform" at William BlairWilliam Blair cut BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a research note on Wednesday.October 30, 2024 | marketbeat.comBioMarin Pharmaceutical’s Strong Q3 Performance and Positive 2024 Outlook Reinforce Buy RatingOctober 30, 2024 | markets.businessinsider.comBioMarin options imply 5.0% move in share price post-earningsOctober 29, 2024 | markets.businessinsider.comBiomarin Pharmaceutical Inc. Q3 Profit Increases, Beats EstimatesOctober 29, 2024 | markets.businessinsider.comBioMarin Pharmaceutical Inc. 2024 Q3 - Results - Earnings Call PresentationOctober 29, 2024 | seekingalpha.comBioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and OutlookOctober 29, 2024 | prnewswire.comChina Universal Asset Management Co. Ltd. Raises Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)China Universal Asset Management Co. Ltd. boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 63.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,991 shares of the biotechnology company's stock afterOctober 29, 2024 | marketbeat.comBioMarin participates in a conference call with JPMorganOctober 29, 2024 | markets.businessinsider.com Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide BMRN Media Mentions By Week BMRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BMRN News Sentiment▼0.610.45▲Average Medical News Sentiment BMRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BMRN Articles This Week▼189▲BMRN Articles Average Week Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SRPT News Today TEVA News Today VYGR News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today NBIX News Today EXEL News Today EXAS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BMRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
